about
Craniorachischisis totalisMaternal periconceptional occupational pesticide exposure and neural tube defectsValproic acid teratogenicity: a toxicogenomics approachEpilepsy during pregnancy: focus on management strategiesValproate and spina bifidaRibonucleotide reductase subunit R1: a gene conferring sensitivity to valproic acid-induced neural tube defects in miceA structured approach to brain injury rehabilitationA method for human teratogen detection by geometrically confined cell differentiation and migrationNeural tube defects--disorders of neurulation and related embryonic processes.Neural tube defects: recent advances, unsolved questions, and controversies.Update on new developments in the study of human teratogens.Permeation across hydrated DPPC lipid bilayers: simulation of the titrable amphiphilic drug valproic acid.The effects of lithium, valproic acid, and carbamazepine during pregnancy and lactation.Major malformations with valproic acid.Recommendations on the use of folic acid supplementation to prevent the recurrence of neural tube defects. Clinical Teratology Committee, Canadian College of Medical Geneticists.Looking for causes of neural tube defects: where does the environment fit in?The epidemiology of disasters and adverse reproductive outcomes: lessons learned.Review of neural tube defects: risk factors in parental occupation and the environmentAnticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in miceBrief report novel mechanism for valproate-induced teratogenicity.Periconceptional maternal alcohol consumption and neural tube defects.Clinical utility of folate-containing oral contraceptives.Working towards a risk prediction model for neural tube defects.Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice.A standardized human embryoid body platform for the detection and analysis of teratogensGenetic variation in genes of folate metabolism and neural-tube defect risk.Use of antiepileptic medications in pregnancy in relation to risks of birth defectsThe continuing challenge of understanding, preventing, and treating neural tube defects.Valproic acid increases expression of methylenetetrahydrofolate reductase (MTHFR) and induces lower teratogenicity in MTHFR deficiencyAcephalous lamb from an in vitro-produced sheep embryo.Intersection of complex genetic traits affecting maternal metabolism, fetal metabolism, and neural tube defect risk: looking for needles in multiple haystacks.Epilepsy and pregnancy--a review of 98 pregnancies.Genetic studies of myelomeningocele.Valproic acid-induced somite teratogenesis in the chick embryo: relationship with Pax-1 gene expression.Potential human developmental toxicants and the role of animal testing in their identification and characterization.Prenatal exposure to environmental factors and congenital limb defects.Interaction between the SLC19A1 gene and maternal first trimester fever on offspring neural tube defects.Associations between post translational histone modifications, myelomeningocele risk, environmental arsenic exposure, and folate deficiency among participants in a case control study in Bangladesh.Inducible 70 kDa heat shock proteins protect embryos from teratogen-induced exencephaly: Analysis using Hspa1a/a1b knockout mice.Teratogenic effects of vigabatrin in TO mouse fetuses.
P2860
Q22336964-7C3C1A6A-C29C-4A5B-9854-41B1CD9D0BE9Q23914646-90F8B86D-5243-4ACF-9295-C50952BDF188Q24813390-70E2A77A-F810-4A7C-80C7-A84744D35626Q28080299-DAC343C8-A966-4914-B764-C6BAD3E08F31Q28340864-140E2032-E23D-4644-A001-0C2D16AC71B2Q28373189-B26D277B-65E1-4B25-9F79-C53132E8F374Q28743263-C4C25C77-4F89-4678-A58C-8F95112107FBQ30650021-63D5140F-83EC-4AEA-AAF3-7434A18E7F63Q33620903-433DC6EF-3BB5-491F-A5EA-E6DB0DE5DF3FQ33620909-E1153D2D-A310-4C07-934B-86EA196F9660Q34123327-570888B2-E178-47D3-BAFF-3AFC4E4FADE6Q34183816-617EF69A-F055-4D6F-912C-CD5179372574Q34349772-DA114AB5-59EA-49B1-9C2F-321E5BB7687BQ34517882-39839C0C-6A65-4E58-9CC7-87699C2EED51Q34707032-00A98007-F1FC-4ACD-851F-5D801F4B5B5BQ34832860-841B7192-5A38-461E-991B-0B4710A1547DQ34847956-B1EE448B-2C46-40AC-A4E6-D99E1EBAEF45Q35031927-0D911364-BC2C-469E-A134-CAEF903B183FQ35045414-30D417C0-A9A0-4777-B461-1D29103C5EC3Q35414137-40D891A8-5A37-4426-AEE3-3F95277A5014Q35618730-71E4D2D4-53F1-4751-815B-809D8CAFDF54Q35940242-67E6FD87-1F46-4D2D-B164-CE4732314961Q36057792-90B7BB45-0E5C-4C26-9608-E60CA5248FADQ36244649-08206E98-AC6E-44C9-914D-8DA673C23B80Q36275388-A3C8E1BF-AC51-478C-9F85-0FF05FF18D9EQ36467477-2A4E102C-5138-4339-BC8B-82295D9ACDBCQ36751405-3F304BFE-0358-4C3D-BC1C-20AE6FC2E25FQ36914843-921EB8CF-7B96-4737-81E8-716B1E73388DQ36952666-7111A693-0E97-42D7-A788-D314E96965F7Q37165888-1EAE9AEC-B879-4ED6-B825-CB4F4526C412Q37695522-4BC259E2-7470-41AC-B6C0-761CC4379BEBQ37786706-63CF0C35-FD16-4499-9834-C0A71E40AC45Q38135224-DBB6A188-9064-49EA-A4F9-FDCBB9B1F7A1Q38354437-36EE9CDB-9818-434D-8EAC-D3CE3B276E8DQ38625359-9C4E4C65-31D6-4102-9A90-A5A766BF9793Q38987429-990B5510-2085-40C3-BA5A-DD2F62A71605Q40204079-149563F6-AC9C-4E37-94A8-3DC05FAD99BFQ40253479-17182FC0-4B71-4712-9BFE-60A821F1862CQ40383650-B1671F4F-4BD6-4B4D-9AD2-CE1E839DBDBFQ42549197-6268452B-C5B8-4E75-AE59-319F7AB96266
P2860
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
1987年论文
@zh
1987年论文
@zh-cn
name
Teratogen update: valproic acid.
@en
Teratogen update: valproic acid.
@nl
type
label
Teratogen update: valproic acid.
@en
Teratogen update: valproic acid.
@nl
prefLabel
Teratogen update: valproic acid.
@en
Teratogen update: valproic acid.
@nl
P2093
P356
P1476
Teratogen update: valproic acid.
@en
P2093
P304
P356
10.1002/TERA.1420350319
P577
1987-06-01T00:00:00Z